Huntington’s disease in Bangladesh
The Lancet has published a very interesting article about HD in Bangladesh that we want to share with you! You
Read more.
First human gene therapy trial in Huntington’s disease
Huntingtin-lowering The focus of the first trial is safety and tolerability – finding out whether there any harmful or unpleasant effects of receiving
Read more.
Pridopidine
Pridopidine is back! Dr. Michael Hayden and his company Prilena, just announced that the Pridopidine clinical trial will be restarted! 
Read more.
New Knowledge about the Huntingtin gene
Breaking news! DURHAM, N.C. — A Duke University research team has identified a new function of a gene called huntingtin,
Read more.
Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington’s
Wave and Roche neck and neck! This is very good news for Huntingtonians world-wide! We attended a very exciting webcast
Read more.
Update from Stronger together, better together conference
“Strange strategy from Roche!” Svein Olaf Olsen- President of the International Huntington Association The President of The International Huntington Association
Read more.
logo
A letter from Roche
The enrolment in the Phase III trial GENERATION HD1 study has been increased from 660 to 801 participants worldwide, as
Read more.
Update: RG6042 Phase III GENERATION HD1 study re-opens
Dear global patient community partners, Following your previous request to be kept up to date on the clinical development programme
Read more.
The inaugural conference of Huntington Disease Society of India
This picture was taken at the Inaugural conference of Huntington Disease Society of India. Among others, Svein Olaf Olsen –
Read more.
E-health for Huntington’s patients and families
What’s is Healthe-RND?  Huntington’s disease (HD) requires intensive cooperation between different medical disciplines and services, so-called ‘multidisciplinary care’.  Given the
Read more.